Published on August 30, 2021
New and Emerging Combination Therapies for CLL
With promising new combination therapies, will chronic lymphocytic leukemia (CLL) patients eventually be able to go off treatment? Watch Patient Power co-founder and CLL patient, Andrew Schorr, talk to Julie Vose, MD, MBA, Chief of the Oncology/Hematology Division in the Department of Internal Medicine at the University of Nebraska Medical Center and Brian T. Hill, MD, PhD, Director of Lymphoid Malignancies at the Cleveland Clinic Taussig Cancer Institute. They discuss the future of CLL combination therapies, what is the horizon, and if they could become first-line therapies soon.
Support for this series has been provided by AbbVie, Inc. and Genentech, Inc. Patient power maintains complete editorial control and is solely responsible for program content.